Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

Research Watch

Tumor Hypoxia Suppresses TET Activity to Enhance DNA Methylation

DOI: 10.1158/2159-8290.CD-RW2016-158 Published October 2016
  • Article
  • Info & Metrics
Loading
  • Major finding: Tumor hypoxia reduces TET activity and causes tumor suppressor gene hypermethylation and repression.

  • Mechanism: Decreased TET activity leads to reduced 5hmC and enhanced promoter hypermethylation.

  • Impact: Tumor hypoxia may promote tumor progression in part by regulating DNA methylation.

Tumors exhibit oncogenic epigenetic alterations including global hypomethylation and local promoter hypermethylation that can repress the transcription of tumor suppressor genes and promote cancer cell growth. Oxygen-dependent tet methylcytosine dioxygenase (TET) family proteins catalyze the oxidation of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), resulting in DNA demethylation. 5hmC is frequently lost in cancer, but in the majority of tumors, the underlying mechanism is unclear. Thienpont and colleagues observed that hypoxia induced 5hmC loss in a majority of tested human and murine cell lines, resulting from reduced activity, but not reduced expression, of TETs. DNA-immunoprecipitation sequencing (DIP-seq) revealed global loss of 5hmC in response to hypoxia, predominantly at gene promoters, many of which had concomitant gain of 5mC, and RNA-seq confirmed that expression of these genes was repressed. Data from The Cancer Genome Atlas showed increased promoter hypermethylation in hypoxic tumors, which was associated with reduced gene expression. TET2 and TET3 expression were inversely correlated with hypermethylation, and TET1 and TET3 mutations were positively correlated, supporting a role for reduced TET activity in limiting 5hmC generation and promoting DNA hypermethylation. Additionally, TET enzymes are completely inactivated in IDH1-mutant glioblastoma, and these tumors exhibited extensive hypermethylation and reduced expression of many of the same genes hypermethylated by hypoxia. However, IDH1-mutant glioblastomas exhibited greater methylation than hypoxic glioblastomas, suggesting that hypoxia only partially inactivates TET. In breast tumors, hypoxia induced hypermethylation of the promoters of tumor suppressor genes, but not of oncogenes, and in a mouse model of spontaneous breast tumors, hypoxic areas of the tumor exhibited 5hmC depletion. Reduction of tumor oxygenation further increased 5mC at tumor suppressor gene promoters, and this effect was reversed by normalizing the tumor vasculature. Taken together, these findings demonstrate that hypoxia suppresses TET activity, leading to reduced expression of tumor suppressor genes, and provide a link between hypoxia and DNA methylation.

Thienpont B, Steinbacher J, Zhao H, D'Anna F, Kuchnio A, Ploumakis A, et al. Tumour hypoxia causes DNA hypermethylation by reducing TET activity. Nature 2016 Aug 17 [Epub ahead of print].

  • ©2016 American Association for Cancer Research.
PreviousNext
Back to top
Cancer Discovery: 6 (10)
October 2016
Volume 6, Issue 10
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Tumor Hypoxia Suppresses TET Activity to Enhance DNA Methylation
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Tumor Hypoxia Suppresses TET Activity to Enhance DNA Methylation
Cancer Discov October 1 2016 (6) (10) OF7; DOI: 10.1158/2159-8290.CD-RW2016-158

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Tumor Hypoxia Suppresses TET Activity to Enhance DNA Methylation
Cancer Discov October 1 2016 (6) (10) OF7; DOI: 10.1158/2159-8290.CD-RW2016-158
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • Inhibitory CD161 Receptor Is Expressed on Glioma-Infiltrating T Cells
  • Combination Immune Checkpoint Blockade Promising in Operable NSCLC
  • Anti-CTLA4 Perturbs Treg-Based Immunosuppression in Glycolysis-Low Tumors
Show more Research Watch

Epigenetics

  • H1 Loss Increases Accessibility of Stemness Genes to Drive Lymphoma
  • Wilms Tumor–Associated ENL Mutants Cause Target-Gene Overexpression
  • Cancer-Associated DNMT3A Is Recruited by H3K36me2 to Methylate DNA
Show more Epigenetics
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement